Chapter 2

Financials and Estimates

Over FY2023–FY2025 Vital Farms turned a break-even business into a real one: revenue rose from $471.9M to $759.4M, gross margin held near 38%, and diluted EPS went from $0.59 to $1.44. The forward picture is the mirror image — company guidance and consensus both point to FY2026 as a margin and earnings trough, with a partial recovery in FY2027. Whether that trough is real or still being cut is the number that matters most here.

The three-year record

The trailing three years are the strongest in the company's public history. Net revenue compounded at roughly 27% a year, but the more important change is below the top line: the FY2022 operating margin was 0.6% — essentially break-even — and by FY2025 it was 11.6%. Gross margin stepped up from ~30% to ~38% and stayed there. This is a business that earned an 18.9% return on equity in FY2025, not the marginally-profitable grower it was three years earlier.

Source: FY2025 Annual Report (Form 10-K), Consolidated Statements of Income [1]; return on equity derived from reported financials.

Source: FY2023–FY2025 Annual Reports (Form 10-K), Consolidated Statements of Income [2].

A detail inside the FY2025 top line matters for what comes next. Of the $153.1M revenue increase, $78.3M came from volume and $74.9M from price/mix [2]. Roughly half of last year's growth was price, at a time when inflated conventional-egg prices let the company hold a wide premium. That is the same lever now running in reverse (The Egg Premium).

Margins expanded, then held

The five-year margin path shows the inflection clearly. Gross margin fell in FY2022 as input costs spiked, then recovered and expanded to a high-30s plateau. Operating and net margins moved from near-zero to double digits over the same span — the difference between a company covering its costs and one generating meaningful profit.

Source: derived from reported financials, FY2021–FY2025 Annual Reports (Form 10-K), Consolidated Statements of Income [3].

Cash conversion inverted in FY2025

For most of this period Vital Farms converted profit to cash cleanly: free cash flow was positive $39.4M in FY2023 and $36.2M in FY2024. FY2025 broke that pattern. Operating cash flow fell to $33.7M — held back by a working-capital build, with inventory rising from $23.7M to $66.5M — while capital expenditure jumped to $82.0M as the Vital Crossroads plant construction ramped [4]. The result was negative free cash flow of $48.2M. The cash outflow was a growth investment, not an operating loss — but it drained the balance sheet at the same moment demand was slowing.

Source: FY2021–FY2025 Annual Reports (Form 10-K), Consolidated Statements of Cash Flows [5].

The balance sheet absorbed it without stress. Cash fell from $150.6M to $48.8M over FY2025 — almost entirely the capex step-up — but the company still ended the year with $351.3M of equity, $149.4M of retained earnings, and no funded debt [6]. That debt-free position is what makes a loss-making year survivable rather than existential.

The forward view: a guided trough

The forward numbers are where the case turns. Following a weak first quarter, management cut FY2026 guidance to net revenue of $775M–$800M and adjusted EBITDA of just $0–$10M [7]. Revenue therefore still grows modestly off FY2025's $759.4M; profit is what collapses. Consensus lines up almost exactly: FY2026 revenue of $775.3M (+2.1%) and a diluted loss of about $0.42 per share, versus the $1.44 earned in FY2025.

Sources: FY2024–FY2025 actuals per Consolidated Statements of Income [8]; FY2026–FY2027 consensus estimates, as reported.

Both the company and the Street then call for FY2026 to be the low point. Management describes 2026 as "a low watermark for margins in this cycle," expects underlying gross margin back to 30% by late Q4, and adjusted EBITDA margin back to double digits in FY2027 [9]. Consensus agrees on shape: FY2027 revenue of roughly $848.6M (+9.5%) and EPS back to about $0.44.

Sources: company FY2026 guidance per Q1 FY2026 earnings call [10]; consensus estimates, as reported.

What Q1 FY2026 actually showed

The first quarter is the evidence behind the reset. Net revenue of $187.2M still grew 15.4%, but gross margin fell to 28.3% from 38.5% a year earlier, and the company swung to a $1.5M net loss from $16.9M of net income; adjusted EBITDA was $5.0M (2.7% of revenue) against $27.5M (16.9%) the year before [11]. The margin damage is a mix of a widened price gap forcing promotional and price investment, and roughly $32M of one-year "supply management" costs — selling excess eggs into the low-value breaker channel and paying farmers to pause production — that management expects to concentrate in the first half [12].

Management is defending cash rather than earnings this year: FY2026 capex was cut by roughly $75M — chiefly by slowing the Vital Crossroads build and pausing the accelerator farms — to a $70M–$75M range, the butter business is being exited (freeing about $25M of cash and lifting gross margin 150–200bps from 2027), and remote headcount was reduced about 10% [13]. Even so, free cash flow is expected to stay negative in FY2026, funded from the existing cash and investment position and the credit facility. The company held $51.4M of cash and marketable securities with no debt at quarter-end, and repurchased over one million shares for $20M with $80M of authorization remaining [14].

Is FY2026 a true one-year trough?

The bull reading is straightforward and, on the current evidence, defensible: revenue keeps growing, the FY2026 profit collapse is driven by identifiable and largely one-year costs, the balance sheet carries no debt, and both management and consensus model a return to positive EPS and double-digit EBITDA margin in FY2027. Nothing in the three-year record suggests the underlying model stopped working — the FY2022–FY2025 margin build was real.

The counter-fact sits in the estimates themselves. Ninety days before this snapshot, consensus had FY2026 EPS at about +$1.01 and FY2027 at +$1.31; today those are -$0.42 and +$0.44 (consensus estimates, as reported). The trough has been cut repeatedly, and the guidance that anchors it is explicitly conditional: it assumes retail prices and price gaps stabilize at current levels, and warns that further erosion would require more price investment and additional cost [15].

What the price implies

At $13.02, Vital Farms carries a market value near $599M against roughly $51M of net cash — an enterprise value around $548M, or about 0.7 times FY2025 revenue. On trailing FY2025 earnings the multiple is about 9 times; on the consensus FY2027 recovery EPS of $0.44 it is closer to 30 times, and FY2026 has no positive earnings to divide by. The analyst mean price target of $12.00 sits slightly below the current quote, in a $10–$16 range.

Sources: share price, market capitalization and analyst targets per consensus data, as reported; net cash and sales multiple derived from FY2025 Annual Report balance sheet and income statement [16].

The multiple is undemanding on trailing numbers and on sales, and unremarkable on the FY2027 recovery earnings — which is another way of saying the stock is priced close to the trough it is being asked to work through, with limited premium for the recovery holding. For an investor sizing margin of safety, the debt-free balance sheet is the anchor; the open question is how many more quarters the reset takes and how deep the earnings floor finally proves to be.